ONMD ONEMEDNET CORP

31 Million Patient Journeys, One Mission

31 Million Patient Journeys, One Mission

OneMedNet joins Datavant’s Real-World data ecosystem to Power Next-Gen Healthcare

MINNEAPOLIS, March 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet, an AI-powered Real World Data leader, has announced a collaboration with Datavant, a health data platform, to provide access to tokenized, purpose-built data for life sciences and medical research through Datavant’s health data ecosystem. Leveraging OneMedNet’s network of 31M patients, 121M+ clinical studies—EMR insights like images, ECGs, and notes—this collaboration enables life sciences companies to integrate claims data for a full view of patient journeys tailored to specific diseases.

By integrating OneMedNet’s patient tokens into the Datavant ecosystem of more than 300 real-world data partners, customers seeking Real-World Data for specific patient populations can effortlessly discover and access it. This streamlined process enhances longitudinal data visibility and connectivity, enabling researchers and organizations to identify the precise insights they need to speed innovative treatments and drive impactful outcomes.

“Linking healthcare data securely unlocks transformative potential for researchers,” said Aaron Green, OneMedNet CEO. “Cross-referencing our data with existing datasets through the Datavant ecosystem confirms its unique value, ensuring it’s additive, non-redundant and cost-effective. This collaboration highlights OneMedNet’s leadership in medical innovation through AI, robust platforms, and seamless integration—and will accelerate the ability of organizations to advance evidence-based solutions and access critical patient-level insights, all while safeguarding privacy.”

About OneMedNet Corporation

OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

OneMedNet Contacts:

Michael Wong, VP Marketing

Email:

SOURCE: ONEMEDNET CORPORATION



EN
10/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONEMEDNET CORP

 PRESS RELEASE

OneMedNet Reports 80% Reduction in Debt Enabling Focus On Growth

OneMedNet Reports 80% Reduction in Debt Enabling Focus On Growth MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced its financial results for the second quarter ended June 30, 2025, including its significantly improved balance sheet. Second Quarter and First Half 2025 Financial Highlights Improved Balance Sheet: Due to the combination of debt conversions, vendor repayments, and highly discounted debt settlements, total liabilities have be...

 PRESS RELEASE

OneMedNet Reports Over 25% Expansion of iRWD™ Network, Encompassing Cl...

OneMedNet Reports Over 25% Expansion of iRWD™ Network, Encompassing Clinical Data alongside Aggregate Health Economics and Social Determinant Insights from 5 Billion Administrative Records, Fueling Growth in AI-Powered Healthcare Data Over 1,750 provider sites and access to 136 million clinical exams positions OneMedNet for accelerated revenue and market penetration MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced today a greater than 25% expansion of its proprietary ...

 PRESS RELEASE

Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project U...

Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms Reduce development timelines and costs, while improving access to life-saving treatments VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), has been selected by OneMedNet Corporation (Nasdaq: ONMD) to lead a high-impact data analytics initiative focused on imp...

 PRESS RELEASE

OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting S...

OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting Strategic Progress MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced today that Aaron Green, President and CEO, issued the following letter to shareholders and other stakeholders of the Company: Dear OneMedNet Shareholders, Partners, and Family, Following a year of significant progress, OneMedNet is navigating 2025 with strong momentum, making substantial strides in expanding our market presence, enh...

 PRESS RELEASE

OneMedNet Announces Additional $3.7 Million of Funding in Private Plac...

OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that it has entered into agreements with accredited investors in private placement transactions at $0.42 per share of common stock that resulted in gross proceeds of approximately $3.7 million, before deducting fees and expenses payable by th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch